Delaware |
001-11460
|
31-1103425 |
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
10355 Science Center Drive,
Suite 150
|
||
San Diego, California
|
92121
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.005 per share
|
BTX |
The Nasdaq Stock Market LLC
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
Number
|
Description
|
|
Marcum, LLP letter dated April 19, 2022.
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Brooklyn ImmunoTherapeutics, Inc.
|
||
Dated: April 19, 2022
|
By:
|
/s/ Howard J. Federoff
|
Howard J. Federoff
|
||
Chief Executive Officer and President
|